Genomic Vision Launches EasyScan, the First Digital Service for Analyzing DNA by Molecular Combing
11 Juillet 2016 - 9:05AM
Business Wire
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), DNA
molecular combing specialist that develops tests for the
diagnostics market and tools for the life sciences research market,
announces the launch of EasyScan, the first digital service for
analyzing DNA by molecular combing. Designed to meet the needs of
researchers studying DNA replication, this new service will allow
them to benefit, without leaving their laboratory, from the
powerful technologies developed by Genomic Vision for the
visualization and detection of combed DNA fibers and the
measurement of dynamic parameters for DNA replication. More
generally, it allows the automatization of each stage of DNA
replication analysis. Researchers send their samples to Genomic
Vision and have secure direct online access to their results.
With EasyScan, Genomic Vision is generalizing access to its
innovative technologies by opening up its laboratory. Researchers
will now be able to benefit remotely from the automated molecular
combing platform, FiberVision® and the FiberStudio software, via
the Company’s WebApp. This powerful software has been specifically
developed by Genomic Vision for the analysis of the results of
molecular combing. It allows the detection, measurement and
interpretation of hybridization and signs of replication on the
combed DNA.
Every sample that is received is recorded and tied to a
privatized client account in the EasyScan database, thus
guaranteeing its traceability throughout the process. Once they
have been scanned and analyzed, the results are immediately
accessible so that they can be studied via secure access to Genomic
Vision’s WebApp. The results are also securely stored there.
Professor Nick Rhind (University of Massachusetts Medical
School), adds: “The EasyScan platform is a great advance in
molecular combing that should bring the technology within the reach
of many more labs. The automated scanning and direct access to our
data on Genomic Vision’s WebApp make our experiments much faster
and more efficient."
A solution that addresses the needs of many clients.
« In many laboratories around the world, researchers spend
long hours, or even many days, observing their microscope slides
and performing the measurements necessary to their studies. By
offering them EasyScan, Genomic Vision allows them to concentrate
on the essentials, their experimentations and results in a few
hours.» explains David Del Bourgo, Genomic Vision’s.Director of
Sales and Marketing.
For Genomic Vision, EasyScan’s launch confirms its commercial
expansion within its strategy targeting the LSRT market.“EasyScan
represents an additional step in Genomic Vision’s strategy on the
LSRT market, particularly in the field of replication, for which
Genomic Vision offers a panel of strong, fast and extremely
reliable technologies. ”, concludes Aaron Bensimon, Genomic
Vision’s co-founder and Chairman.
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a DNA molecular combing
specialist that develops tests for the diagnostics market and tools
for the life sciences research market. Using its innovative
technology that allows the direct visualization of individual DNA
molecules, Genomic Vision detects quantitative and qualitative
variations in the genome that are at the origin of numerous serious
pathologies. The Company is developing a solid portfolio of tests
that initially target breast and colon cancers. Since 2013, the
Company has marketed the CombHelix FSHD test for identifying
facioscapulohumeral dystrophy (FSHD), a myopathy that is difficult
to detect. It is marketed in the United States through a strategic
alliance with Quest Diagnostics, the American leader in diagnostic
laboratory tests, and in France directly by the Company. Genomic
Vision has been listed on Compartment C of Euronext Paris since
April 2014.
ABOUT MOLECULAR COMBING
DNA molecular combing technology significantly improves the
structural and functional analysis of DNA molecules. DNA fibers are
stretched over glass slides, as if "combed", and uniformly aligned
over the entire surface. It is then possible to identify genetic
anomalies by locating specific genes or sequences in the patient's
genome using genetic markers, a technique developed by Genomic
Vision and patented under the name Genomic Morse Code. This
exploration of the entire genome at high resolution via a simple
analysis enables the direct visualization of genetic anomalies that
are undetectable by other technologies.
For further information, please go to: www.genomicvision.com
Member of CAC® Mid & Small, CAC® All-Tradable
and EnterNext© PEA-PME 150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160711005461/en/
Genomic VisionAaron Bensimon, Tel.: +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorKalimaRelations
PresseEstelle Reine-AdélaïdeFlorence CalbaTel.: +33 6 17 72 74 73 /
+33 1 44 90 82 54era@kalima-rp.frorNewCapInvestor Relations
/ Strategic CommunicationsDušan Orešanský / Emmanuel Huynh, Tel.:
+33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024